Repaglinide in the management of new-onset diabetes mellitus after renal transplantation

American Journal of Transplantation

Volumn 6, Issue 4, 2006, Pages 842-846

  Turk T ^a   Pietruck, F ^a   Dolff, S ^a   Kribben, A ^a   Janssen, O E ^a   Mann, K ^a   Philipp, T ^a   Heemann, U ^b   Witzke, O ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

New onset diabetes mellitus; Renal transplantation; Repaglinide

Indexed keywords

CYCLOSPORIN A; HEMOGLOBIN A1C; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; REPAGLINIDE; ROSIGLITAZONE; SHORT ACTING DRUG; TSUKUBAENOLIDE; ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; GLUCOSE; METFORMIN; MYCOPHENOLATE MOFETIL; ORAL ANTIDIABETIC AGENT; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG SUBSTITUTION; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; KIDNEY TRANSPLANTATION; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BODY WEIGHT; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; NAUSEA; NEW ONSET DIABETES MELLITUS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

CARBAMATES; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PIPERIDINES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 33644779043     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01250.x     Document Type: Article

References (18)

1. Cosio FG Kudva Y Velde M et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation Kidney Int 2005 67 2415 2421
2. Sumrani NB Delaney V Ding ZK et al. Diabetes mellitus after renal transplantation in the cyclosporine era: An analysis of risk factors Transplantation 1991 51 343 347
3. Vesco L Busson M Bedrossian J et al. Diabetes mellitus after renal transplantation Transplantation 1996 61 1475 1478
4. Montori VM Basu A Erwin PJ Velosa JA Gabriel SE Kudva YC Posttransplantation diabetes: A systematic review of the literature Diabetes Care 2002 25 583 592
5. Pirsch JD Miller J Deierhoi MH Vincenti F Filo RS A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation Transplantation 1997 63 977 983
6. Hirano Y Hisatomi A Ohara K Noguchi H The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas Transplantation 1992 54 883 887
7. Tamura K Fujimura T Tsutsumi T et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding-protein-12 in pancreatic (beta)-cell Transplantation 1995 59 1606 1613
8. Davidson J Wilkinson A Dantal J et al. New-onset diabetes after transplantation: 2003 international consensus guidelines Transplantation 2003 75 Suppl SS3 24
9. Baldwin D Duffin KE Rosiglitazone treatment of diabetes mellitus after solid organ transplantation Transplantation 2004 77 1009 1014
10. Pietruck F Kribben A Ngo Van T et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation Transpl Int 2005 18 483 486
11. Marceille JR Goins JA Soni R Biery JC Lee TA Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin Pharmacotherapy 2004 24 1317 1322
12. Fonarow GC Approach to the management of diabetic patients with heart failure: Role of thiazolidinediones Am Heart J 2004 148 551 558
13. Yale JF Oral antihyperglycemic agents and renal disease: New agents, new concepts J Am Soc Nephrol 2005 16 Suppl 1 S7 S10
14. Bidstrup TB Bjornsdottir I Sidelmann UG Thomsen MS Hansen KT CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide Br J Clin Pharmacol 2003 56 305 324
15. Avignon A Radauceanu A Monnier L Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes Diabetes Care 1997 20 1822 2826
16. Standl E Füchtenbusch M The role of oral antidiabetic agents: Why and when to use an early-phase insulin secretion agent in type 2 diabetes mellitus Diabetologica 2003 46 Suppl M30 M36
17. Plosker GL Figgitt DP Repaglinide: A pharmacoeconomic review of its use in type 2 diabetes mellitus Pharmacoeconomics 2004 389 411
18. Thervet E Legendre C Beaune P Anglicheau D Cytochrome P450 3A polymorphisms and immunosuppressive drugs Pharmacogenomics 2005 6 37 47